Download Brochure
X
Semaglutide API
CAS Number: 910463-68-2
Semaglutide API
Therapeutic Category
Anti-Diabetic
API Technology
Peptide
Dose Form
Injectable
Dr Reddy's Development Status
Under-Development
Available Regulatory Filing
To be filed
Mechanism of Action
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors.
The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme.
Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor
Delay in gastric emptying in the early postprandial phase.
Indication
OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Limitations of Use:
- Not recommended as first-line therapy for patients inadequately controlled on diet and exercise
- Has not been studied in patients with a history of pancreatitis. Consider another antidiabetic therapy
- Not indicated for use in type 1 diabetes mellitus or treatment of diabetic ketoacidosis
Dr. Reddy's Expertise
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Semaglutide API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Semaglutide API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
Related Resources
Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API
Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, with 94% sequence homology to human GLP-1 indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
In this whitepaper, we look at Dr. Reddy’s Semaglutide, a synthetic peptide identical to the innovator molecules. As the innovator molecule and unlike most generic versions in the market, it is neither a base addition salt (Sodium, Potassium, and the likes) nor an acid addition salt (Acetate, Trifluoroacetate, Hydrochloride, and the likes).
Dr. Reddy’s provides a unique end-to-end product offering where customers can choose from the following business models:
- API purchase
- API + device purchase
- Combination of API and Salcaprozpate sodium (SNAC) for oral formulation
- Finished formulations purchase
To know more about our API offerings, please read the White paper on Semaglutide by filling the contact from below.
Read More
Disclaimer
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.
FAQs
observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting).
The safety dose for Semaglutide is 2MG/1.5ML (1.34MG/ML).
Semaglutide is used to treat type 2 diabetes mellitus
It belongs to the class of glucagon like peptide-1 (GLP-1) analog
Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at [email protected].
Insights Delivered
Sign-up for our email service to get Market and Product insights and updates right to your digital doorstep
The categories of personal information collected in this form include name, company, and contact information etc. The personal information collected will be used for exploratory discussions on contract manufacturing, marketing and to perform research and analytics and others. For more information about the categories of personal information collected by Dr.Reddy's and the purposes for which Dr.Reddy's uses personal information, visit https://api.drreddys.com/privacy-policy.